文献速递性腺与生殖内分泌肥胖与代谢综合征

多囊卵巢综合征女性的抑郁、焦虑与代谢综合征风险:一项纵向研究

Depression, Anxiety, and Risk of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Longitudinal Study.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该回顾性纵向队列研究(2008-2022年,中位随访7年)纳入321例高雄激素型多囊卵巢综合征患者,比较有或无抑郁和/或焦虑史者发生代谢综合征的风险。结果显示,抑郁和/或焦虑史增加代谢综合征风险(aHR 1.45,95%CI 1.02-2.06,P=.04),主要由抑郁驱动(aHR 1.56,95%CI 1.10-2.20,P=.01)。

要点

  • 多囊卵巢综合征患者中,有抑郁和/或焦虑史者发生代谢综合征的风险升高(aHR 1.45)。
  • 抑郁与代谢综合征的关联更强(aHR 1.56),焦虑的独立贡献未明确。
  • 作者建议在多囊卵巢综合征诊断时及后续随访中按指南筛查抑郁和焦虑。

核心结论

  • 多囊卵巢综合征患者合并抑郁和/或焦虑时发生代谢综合征的风险高,其中抑郁与代谢综合征的关联更强。

研究设计与样本

  • 回顾性纵向队列研究,2008-2022年,在三级医疗门诊进行,中位随访7年。
  • 纳入321例高雄激素型多囊卵巢综合征患者,且至少有2次间隔≥3年的代谢综合征评估。

主要发现

  • 首次就诊时,33.0%有抑郁和/或焦虑史,其中三分之一被处方抗抑郁药或抗焦虑药。
  • 抑郁和/或焦虑增加研究期间发生代谢综合征的风险(aHR 1.45,95%CI 1.02-2.06,P=.04)。
  • 有抑郁和/或焦虑史者代谢综合征发病率为75.3例/100人年,无此病史者为47.6例/100人年(P=.002)。
  • 该风险主要由抑郁驱动(aHR 1.56,95%CI 1.10-2.20,P=.01)。

临床怎么用

  • 作者认为,研究结果突出表明迫切需要在多囊卵巢综合征诊断时及后续随访中按指南筛查抑郁和焦虑,以促进代谢监测和早期干预的风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with polycystic ovary syndrome (PCOS) are at high risk of depression, anxiety, and metabolic syndrome (MetSyn), a key predictor of cardiovascular disease. The impact of depression and/or anxiety on MetSyn is unknown in this population. OBJECTIVE: To compare the risk of developing MetSyn in patients with PCOS with and without a history of depression and/or anxiety. METHODS: Retrospective longitudinal cohort study (2008-2022) with median follow-up of 7 years at a tertiary care ambulatory practice. Patients with hyperandrogenic PCOS and at least 2 evaluations for MetSyn ≥3 years apart (n = 321) were included. The primary outcome was risk of developing MetSyn. We hypothesized that this risk would be higher with a history of depression and/or anxiety. RESULTS: At the first visit, 33.0% had a history of depression and/or anxiety, with a third prescribed antidepressants or anxiolytics. Depression and/or anxiety increased risk of developing MetSyn during the study period (adjusted hazard ratio [aHR] 1.45, 95% CI 1.02-2.06, P = .04) with an incidence of MetSyn of 75.3 compared with 47.6 cases per 100 person-years among those without (P = .002). This was primarily driven by depression (aHR 1.56, 95% CI 1.10-2.20, P = .01). CONCLUSION: Patients with PCOS and depression and/or anxiety have a high risk of developing MetSyn, with a stronger association between depression and MetSyn. Our findings highlight the urgent need for guideline-directed screening for depression and anxiety at time of diagnosis of PCOS as well as screening at subsequent visits to facilitate risk stratification for metabolic monitoring and early intervention in this high-risk group.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lee IT, Rees J, King S, et al. Depression, Anxiety, and Risk of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Longitudinal Study. J Clin Endocrinol Metab. 2025. PMID: 38609160. doi:10.1210/clinem/dgae256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。